Search Within

Tiffany A Traina

Formats
  1. Meeting Abstract (137)
  2. Journal Article (95)
  3. Book Section (8)
  4. Review (6)
  5. Book Whole (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Breast Medicine Service (250)
  2. Department of Medicine (250)
  3. Solid Tumor Oncology Division (250)
  4. Survivorship Research (250)
  5. Epidemiology and Biostatistics (99)
  6. Biostatistics Service (85)

More Groups

People
  1. Clifford Hudis (95)
  2. Sujata Patil (62)
  3. Ayca Gucalp (59)
  4. Larry Norton (56)
  5. Maura Dickler (34)
  6. Diana Lake (33)

More People

Years
  1. 2025 (3)
  2. 2024 (16)
  3. 2023 (8)
  4. 2022 (13)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (76)
  2. Cancer Research (44)
  3. Breast Cancer Research and Treatment (16)
  4. Annals of Oncology (14)
  5. Clinical Cancer Research (11)
  6. Clinical Breast Cancer (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (77)
  2. American Association for Cancer Research (55)
  3. Springer (33)
  4. Elsevier Inc. (23)
  5. Oxford University Press (16)
  6. Future Medicine (5)

More Publishers

Results (250)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PARP (poly ADP-ribose polymerase) inhibitors for locally advanced or metastatic breast cancer
    Review

    Taylor, A. M.; Chan, D. L. H.; Tio, M.; Patil, S. M.; Traina, T. A.; Robson, M. E.; Khasraw, M.
    Cochrane Database of Systematic Reviews (2021)

    Fulltext@MSK | Save
  • Tenacity: A phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer
    Meeting Abstract

    Traina, T. A.; Cobain, E. F.; Evron, E.; Duksin, C.; Gordon, G.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)
    Meeting Abstract

    Krop, I.; Yonemori, K.; Takahashi, S.; Inoue, K.; Nakayama, T.; Iwata, H.; Toyama, T.; Yamamoto, Y.; Takahashi, M.; Osaki, A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Tolaney, S. M.; Punie, K.; Loirat, D.; Oliveira, M.; Kalinsky, K.; Zelnak, A.; Aftimos, P.; Dalenc, F.; Sardesai, S.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer
    Meeting Abstract

    DieĢras, V.; Weaver, R.; Tolaney, S. M.; Bardia, A.; Punie, K.; Brufsky, A.; Rugo, H. S.; Kalinsky, K.; Traina, T.; Klein, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicentre, open-label, randomised, phase 3 study
    Journal Article

    Mayer, E. L.; Dueck, A. C.; Martin, M.; Rubovszky, G.; Burstein, H. J.; Bellet-Ezquerra, M.; Miller, K. D.; Zdenkowski, N.; Winer, E. P.; Pfeiler, G.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • American Society of Clinical Oncology Road to Recovery report: Learning from the COVID-19 experience to improve clinical research and cancer care
    Guidelines

    Pennell, N. A.; Dillmon, M.; Levit, L. A.; Moushey, E. A.; Alva, A. S.; Blau, S.; Cannon, T. L.; Dickson, N. R.; Diehn, M.; Gonen, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The path to improving breast cancer outcomes: Targeting the androgen receptor pathway in triple-negative breast cancer [Interview]
    Miscellaneous

    Traina, T. A.
    Oncology (Norwalk) (2020)

    Fulltext@MSK | Save
  • The impact of PI3K inhibitors for the treatment of patients with breast cancer
    Review

    Traina, T. A.
    Oncology (Norwalk) (2020)

    Fulltext@MSK | Save
  • A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer
    Journal Article

    Krop, I.; Abramson, V.; Colleoni, M.; Traina, T.; Holmes, F.; Garcia-Estevez, L.; Hart, L.; Awada, A.; Zamagni, C.; Morris, P. G.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save